Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Chronic HFrEF (Japan) – Randomized Phase 3
jRCT2080223469Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Dapagliflozin arm with Placebo arm (2 arms). Primary endpoint: Incidence of worsening heart failure or cardiovascular death. Started Mar 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCT2080223469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223469.